Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

See Why Does HC Wainwright Maintain Neutral On Akebia Stock

Akebia Therapeutics Inc (NASDAQ: AKBA) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022.

FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff

FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff

Battered after a surprising FDA rejection for its lead pipeline program last week, Akebia Therapeutics Inc (NASDAQ:AKBA) has layoffs that are now on the way. In a filing with the SEC, Akebia said the FDA issued a partial clinical hold on the drug's pediatric studies. As a result, Akebia will suspend all vadadustat studies…

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Inc (NASDAQ: NERV) received the

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ:HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule. "We believe WTX-613 has the potential to minimize the toxicity associated with systemic IFNα therapy, preferentially delivering IFNα to tumors, and thereby expanding its clinical utility in treating…

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022

Biophytis SA (NASDAQ:BPTS) said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos (BIO101) trial in sarcopenia. Enrollment is expected to start in 2H of 2022 in the SARA Phase 2 trial. In October 2021, sarconeos at the highest dose of 350 mg…

Mail-order abortion pills become next US reproductive rights battleground

The FDA has dropped a requirement for the abortion drug mifepristone to be picked up in person – but some Republicans states are clamping down

The Guardian - US

inkl

Read news from The Economist, FT, and more,
with one subscription

Morning Brief: Top Stories Dominating Financial Media on Thursday, April 7

Morning Brief: Top Stories Dominating Financial Media on Thursday, April 7

Reuters Here’s Why HP Shares Are Trading Higher Premarket

Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD

Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD

Adverum Biotechnologies Inc (NASDAQ: ADVM) received feedback via a

FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ

FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ

According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for protection against the evolving virus.

The high-stakes push to get COVID vaccines to young children

The high-stakes push to get COVID vaccines to young children

The Omicron variant and and anti-vaccine backlash are complicating the effort.

These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

40 Stocks Moving In Wednesday's Mid-Day Session

40 Stocks Moving In Wednesday's Mid-Day Session

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

US experts discuss COVID boosters for the fall and beyond

Vaccine experts are meeting to discuss the U.S. strategy for future COVID-19 booster campaigns

Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial

Citius Pharmaceuticals Inc (NASDAQ:CTXR) reported topline results from the Phase 3 trial of I/ONTAK (E7777) for persistent or recurrent cutaneous T-cell lymphoma (CTCL). I/ONTAK (E7777) is an engineered IL-2-diphtheria toxin fusion protein. No new safety signals were identified. Citius anticipates filing a marketing application with the FDA in 2H of 2022. The Independent…

Tribune News Service

States weigh shielding doctors' COVID misinformation, unproven remedies

The controversy began in September, more than a year into the pandemic, when the Tennessee Board of Medical Examiners issued a warning to doctors in the state: Spreading misinformation about COVID-19 vaccines could land them in big trouble with the board, including the possible revocation of their medical licenses.

Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Get all your
news in one place.

100's of premium titles.
One news app.

FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation

The Conversation

Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier

Discovering new ways to use existing drugs can come about intentionally or by chance.

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours.

Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy

Experts eye a new game plan for COVID vaccines

An FDA panel mulls long-term strategy for COVID shots

Tribune News Service

Future of COVID boosters comes down to crucial meeting of FDA Advisers

An all-star panel of COVID-19 experts will convene this week to hash out how and when vaccines should be updated to address future variants as the virus continues to rapidly mutate.

The Independent UK

US pulls GSK's COVID drug as omicron sibling dominates cases

U.S. regulators say GlaxoSmithKline’s COVID-19 antibody drug should no longer be used because it is likely ineffective against the latest version of the virus that accounts for most cases

1 … 224 225 226 227

People

Anthony Scaramucci

Rachel Rebouché

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

362,452 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play